Evidence map›Paper›PMID 39525800›Full record

ReviewAnnals of medicine and surgery (2012)2024

Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023.

Abinash Mahapatro, Ali Bozorgi, Sri U J Obulareddy, Shika M Jain, Rohan Reddy Korsapati, Aroon Kumar, Kristina Patel, Saman Soltani Moghadam, Arash Arya, Abdulhadi Jameel Alotaibi and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of medicine and surgery (2012), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Abinash MahapatroHi-Tech Medical College and Hospital, Rourkela, Odisha, India.
Ali BozorgiTehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Sri U J ObulareddyUniversity of Arkansas, Little Rock, Arkansas, USA.
Shika M JainMVJ Medical College and Research Hospital, Bengaluru, India.
Rohan Reddy KorsapatiUniversity of Toledo, Toledo, Ohio, USA.
Aroon KumarBaylor College of Medicine, Houston, USA.
Kristina PatelShenyang North New Area, Shenyang, Liaoning Province, People's Republic of China.
Saman Soltani MoghadamGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Arash AryaDepartment of Internal Medicine III, Halle University Hospital, Halle (Saale), Germany.
Abdulhadi Jameel AlotaibiVision Colleges, Riyadh, Saudi Arabia.
Mohammad-Hossein KeivanlouGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Soheil HassanipourGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Maryam HasanpourGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Ehsan Amini-SalehiGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In recent years, glucagon-like peptide-1 (GLP-1) agonists have garnered increasing attention for their potential cardiovascular benefits beyond glycemic control in patients with diabetes. Understanding the research landscape surrounding GLP-1 agonists and cardiovascular diseases (CVDs) is crucial for informing clinical practice and guiding future research endeavors. This bibliometric analysis aimed to comprehensively assess the scholarly output and trends in this field, shedding light on the evolving landscape of GLP-1 agonists' role in cardiovascular health. Methods: The publications concerning GLP-1 agonists in CVDs were gathered from the Web of Science Core Collection, and visualizations were created utilizing Excel 2019, Cite Space, and VOS viewer software. Results and Conclusion: Using bibliometric and visual methods, the research hotspots and trends regarding GLP-1 agonists in cardiovascular diseases were pinpointed. Additionally, a thriving interest in GLP-1 agonists research within cardiovascular medicine was observed, with a notable surge in publications from 2016 onwards. The analysis revealed that the United States and China are the leading contributors, accounting for over 50% of the total publications. The University of Copenhagen and the University of Toronto emerged as the most prolific institutions in this field. Co-citation analysis highlighted the influential role of landmark clinical trials, such as the LEADER, ELIXA, and EXSCEL. Keyword trend analysis identified the emergence of newer GLP-1 agonists, such as tirzepatide and semaglutide, as well as a growing focus on topics like 'healthy obesity' and chronic kidney disease. These findings suggest that the research landscape is evolving, with a focus on expanding the therapeutic applications of GLP-1 agonists beyond glycemic control. Overall, this bibliometric analysis provided insights into the current state and future directions of research on GLP-1 agonists and their impact on cardiovascular health, guiding future research endeavors, and informing clinical practice.

Indexed as

bibliometric analysiscardiovascular diseasesdiabetes mellitusglucagon-like peptide-1trend

Identifiers

PMID39525800
PMCPMC11543192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.